

CONCEPT NOTE

HIV DRUG RESISTANCE

HIV DRUG RESISTANCE SURVEILLANCE IN COUNTRIES SCALING UP PRE-EXPOSURE PROPHYLAXIS

OCTOBER 2020



HIV DRUG RESISTANCE SURVEILLANCE IN COUNTRIES SCALING UP PRE-EXPOSURE PROPHYLAXIS

HIV drug resistance surveillance in countries scaling up pre-exposure prophylaxis

ISBN 978-92-4-000981-3 (electronic version)

ISBN 978-92-4-000982-0 (print version)

© World Health Organization 2020

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. HIV drug resistance surveillance in countries scaling up pre-exposure prophylaxis. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

CONTENTS

Acknowledgements	v
Acronyms and abbreviations	vi
Definitions	vii
Executive summary	viii
1. Introduction	1
2. Survey purpose	4
3. Survey outcomes	4
3.1 Primary survey outcome	5
3.2 Secondary survey outcome	5
4. Overview of methods	5
4.1 Cross-sectional survey approach	5
4.2 Survey population	6
4.3 Survey eligibility criteria	6
4.3.1 Survey inclusion criteria	6
4.3.2 Survey exclusion criterion	7
4.3.3 Expected number of eligible individuals	6
4.4 Survey participating sites	6
4.5 Laboratory methods	6
4.5.1 Specimen collection, handling, shipment and storage	6
4.5.2 HIV drug resistance genotyping and quality assurance of sequences	6
4.6 Survey limitations	7
5. Implementation considerations	8
5.1 Duration of the survey and enrolment procedure	8
5.2 Convention for assigning survey identification numbers	8
5.3 Data collection	8
5.3.1 Minimum set of individual-level information	8
5.3.2 Survey-level information	9
5.4 Data management	9
5.5 Frequency of the survey	9

6. Data analysis	10
6.1 Primary survey outcome	10
6.2 Secondary survey outcome	10
References	11
Annex 1. Expected number of eligible individuals requiring HIV drug resistance testing	14
Annex 2. Data analysis plan	16
Step 1: create a table summarizing the necessary clinical and demographic information for each individual enrolled	16
Step 2: create a table summarizing the necessary HIV drug resistance information for each individual enrolled	18
Step 3: import the data into Stata	19
Step 4: analyse the data	19
Annex 3. Generic budgets	22

ACKNOWLEDGEMENTS

This technical guidance was written by Amalia Girón-Callejas (Consultant, WHO, Department of Global HIV, Hepatitis and STI Programmes) under the coordination of Silvia Bertagnolio and Rachel Baggaley (WHO Department of Global HIV, Hepatitis and STI Programmes).

The concept note was developed with substantial technical input and revisions by the WHO HIVResNet Surveillance and Monitoring Working Group.

We are most grateful to the HIVResNet members (Chris Archibald, Chunfu Yang, David Dunn, Derval Igoe, Emiliano Bissio, Gillian Hunt, Elliot Raizes, Irene Mukui, John Mellors, Juliana de Fatima Da Silva, Mathieu Maheu-Giroux, Mohamed Chakroun, Steven Reynolds, and Urvi Parikh) for their input and we especially acknowledge the contributions of Michael Jordan (Tufts University School of Medicine, USA), Andrew Phillips (University College London, United Kingdom) and Natalie Dean (University of Florida, USA).

Additionally, the development of this technical guidance benefitted from inputs received from Joe Fitzgibbon (NIH/NIAID, USA), Keith Crawford (NIH/NIAID, USA), Jean-Michel Molina (University Paris, France), and Linda-Gail Bekker (Desmond Tutu HIV Centre, South Africa).

We are also grateful for the contributions provided by WHO staff members, especially Michelle Rodolph, Shona Dalal, Yannis Hodges-Mameletzis, Philippe Glaziou, Giovanni Ravasi and Fatim Cham.

ACRONYMS AND ABBREVIATIONS

3TC	lamivudine
DPV	dapivirine
DTG	dolutegravir
FTC	emtricitabine
HIVResNet	HIV Drug Resistance Network
ISO	International Organization for Standardization
INI	integrase inhibitor
NNRTI	non-nucleoside reverse-transcriptase inhibitor
NRTI	nucleoside reverse-transcriptase inhibitor
PrEP	pre-exposure prophylaxis
TAF	tenofovir alafenamide
TDF	tenofovir disoproxil fumarate
XTC	FTC or 3TC

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_24303

